Investigative protocols assist you with the interpretation of some common laboratory result abnormalities and the investigation of some selected clinical conditions.
They are derived from a set of protocols originally produced by Dr Noel Walmsley. Some of these have now been updated, and further protocols have been added with time - Dr John Roberts.
The range of investigative protocols cover conditions associated with:
Clinical Conditions
| Abbreviation |
IP Title |
| Female |
Evaluation of ?androgen excess and/or hirsutism (female). |
| Female 1 |
Evaluation of female infertility |
| Female 2 |
Evaluation of irregular periods. |
| Female 4 |
Hormonal changes during menstrual cycle |
| HEP B 2 |
Hepatitis B immune status |
| Pot High 1 |
Causes of hyperkalaemia - K+ > 5.0 |
| Prl High 1 |
Causes of hyperprolactinaemia (prolactin > 700 mlU/L) |
Coagulation Tests
| Abbreviation |
IP Title |
| Platelet 1 |
Platelet function analyser |
| Thrombosis 1 |
Risk factors for venous thromboembolism |
| vWF1 |
von Willebrand disease |
Drug Screen Interpretation
| Abbreviation |
IP Title |
| Buprenorphine |
Evaluation of Buprenorphine results. |
| Methadone Metabolite |
Evaluation of EDDP (methadone metabolite) results |
| THC |
Evaluation of Δ9-tetrahydrocannabinol (THC) results |
| UDS1 |
Urine drug screening |
| UDS Amph |
Evaluation of sympathomimetic amine results |
| UDS Barb |
Evaluation of barbiturate results |
| UDS Benzo |
Evaluation of benzodiazepine results |
| UDS Cocaine |
Evaluation of cocaine results |
| UDS Opiate |
Evaluation of opiate results |
| UDS TLC |
Thin layer chromatography |
Endocrine Tests
| Abbreviation |
IP Title |
| TSH High 1 |
Evaluation of an elevated serum TSH (> 4.0 mU/L) |
| TSH Low 1 |
Evaluation of a subnormal serum TSH (< 0.2 mU/L) |
General Biochemistry
| Abbreviation |
IP Title |
| Allergen specific IgE |
Specific IgE levels conferring very high risk. |
| Hypocal |
Evaluation of hypocalcaemia - Ca2+ < 2.2 |
| Bicarb Low |
Causes of low plasma HCO3 - HCO3 < 18 |
| CK High |
Causes of an elevated CK - M > 200 F > 140 |
| Calcium High 1 |
Causes of hypercalcaemia - Ca2+ > 2.6 |
| Calcium High 2 |
Evaluation of hypercalcaemia - Ca2+ > 2.6 |
| Globulin High |
Evaluation of hyperglobulinaemia - globulins > 44 |
| Glucose Low |
Evaluation of hypoglycaemia (plasma glucose < 2.8 mmol/L) |
| LDI |
Evaluation of lactate dehydrogenase isoenzymes (LDI) |
| MI Change |
Cardiac enzyme changes during myocardial infarction |
| Mag Low |
Causes of hypomagnesaemia (Mg < 0.7 mmol/L) |
| Phos High |
Causes of hyperphosphataemia - PO42+ > 1.8 |
| Phos Low |
Causes of hypophosphataemia (mild: 0.5~0.65 mmol/L; severe: < 0.4 mmol/L) |
| Polyuria |
Evaluation of polyuria (urine vol > 3 L/24 hours) |
| Pot High 2 |
Evaluation of hyperkalaemia - K+ > 5.0 |
| Pot High 1 |
Causes of hyperkalaemia - K+ > 5.0 |
| Pot Low 1 |
Causes of hypokalaemia - K+ < 3.0 |
| Pot Low 2 |
Evaluation of hypokalaemia - K+ < 3.0 |
| Sodium Low |
Causes of hyponatraemia - Na+ < 130 |
| Urate High |
Evaluation of hyperuricaemia - urate > 0.45 (male) urate > 0.40 (female) |
Immunology
| Abbreviation |
IP Title |
| Band 1 |
Evaluation of plasma cell dyscrasias |
| Band 2 |
Evaluation of IgM plasma cell dyscrasias |
| Coeliac 1 |
Coeliac disease investigation |
| DNA/ENA |
Anti-dsDNA and anti-ENA antibodies |
| IgA Low 1 |
Evaluation of selective IgA deficiency |
Liver Function Test
| Abbreviation |
IP Title |
| ALP High 1 |
Evaluation of an isolated serum alkaline phosphatase (ALP) elevation - ALP > 180 |
| ALP High 2 |
Serum alkaline phosphatase (ALP) elevation - ALP > 180 |
| ALP High 3 |
Evaluation of an isolated serum alkaline phosphatase (ALP) elevation ? growth related - Age < 19 yrs, 300 < ALP < 400 |
| ALP High 4 |
Serum alkaline phosphatase (ALP) elevation ? growth related - age < 19 yrs, 300 < ALP < 400 |
| ALP High 5 |
Marked serum alkaline phosphatase (ALP) elevation - ALP > 700, age < 5 yrs |
| GGT High 1 |
Causes of an elevated serum gamma glutamyl transferase (GGT) (GGT > 100 U/L) |
| LD High 1 |
Evaluation of an elevated serum LD (> 300 U/L) |
| LFT1 |
Evaluation of a moderate elevation of aminotransferase levels (AST; ALT) - bili < 50, 45 < ALT < 150 |
| LFT2 |
Predominant hepatocellular pathology (ALT or AST > 150 U/L; ALP < 200 U/L) |
| LFT3 |
Evaluation of a LFT pattern not typical of liver disease (elevated LD, AST >> ALT) |
| LFT4 |
Causes of isolated hyperbilirubinaemia - bili > 25, other LFTs normal |
| LFT5 |
Evaluation of isolated hyperbilirubinaemia (bilirubin > 30 mmol/L; other LFTs normal) |
| LFT6 |
Evaluation of jaundice (ALT < 400 U/L; ALP > 350 U/L) |
| LFT7 |
Evaluation of jaundice (ALT > 300 U/L; ALP < 350 U/L) |
| LFT8 |
Evaluation of localised cholestasis (ALP > 180 U/L; ALT < 150 U/L; GGT > 100 U/L; bilirubin < 50 umol/L) |
| LFT9 |
Evaluation of mixed hepatocellular and cholestatic disease (ALP > 180; GGT > 65; ALT or AST > 150) |
Microbiology & Patient Notes
Serology
| Abbreviation |
IP Title |
| Chronic Hepatitis B |
Laboratory testing and treatment. |
| Hep A 1 |
Serological events in acute (self-limiting) hepatitis A infection relative to alanine aminotransferese (ALT) peak |
| Hep B 1 |
Serological events in acute (self-limiting) hepatitis B infection relative to Alanine Aminotransferese (ALT) peak |
| Pertussis 1 |
Treatment of Bordetella pertussis |
Warfarin Management
| Abbreviation |
IP Title |
| Warfarin 1 |
Range of International Normalised Ratio (INR) recommended for specific applications of warfarin therapy |
| Warfarin 2 |
Guidelines for the management of an elevated INR, with or without bleeding |
| Warfarin 3 |
Risk factors for bleeding complications of Warfarin therapy |